208 related articles for article (PubMed ID: 24807155)
21. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
22. The genetics and biology of KRAS in lung cancer.
Westcott PM; To MD
Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
[TBL] [Abstract][Full Text] [Related]
23. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
24. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
25. GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
Xu K; Wang J; Gao J; Di J; Jiang B; Chen L; Wang Z; Wang A; Wu F; Wu W; Shen L; Su X
Oncol Rep; 2016 Sep; 36(3):1672-8. PubMed ID: 27460045
[TBL] [Abstract][Full Text] [Related]
26. ETS1 regulates Twist1 transcription in a Kras
Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
[TBL] [Abstract][Full Text] [Related]
27. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.
Baumgart A; Mazur PK; Anton M; Rudelius M; Schwamborn K; Feuchtinger A; Behnke K; Walch A; Braren R; Peschel C; Duyster J; Siveke JT; Dechow T
Oncogene; 2015 Jan; 34(5):578-88. PubMed ID: 24509876
[TBL] [Abstract][Full Text] [Related]
28. Methylated +322-327 CpG site decreases hOGG1 mRNA expression in non-small cell lung cancer.
Zeng Y; Zhu J; Qin H; Shen D; Lei Z; Li W; Ding Z; Huang JA; Liu Z
Oncol Rep; 2017 Jul; 38(1):529-537. PubMed ID: 28586012
[TBL] [Abstract][Full Text] [Related]
29. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
30. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic inactivation of laminin-5-encoding genes in lung cancers.
Sathyanarayana UG; Toyooka S; Padar A; Takahashi T; Brambilla E; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Jul; 9(7):2665-72. PubMed ID: 12855645
[TBL] [Abstract][Full Text] [Related]
32. Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.
Tan DS; Haaland B; Gan JM; Tham SC; Sinha I; Tan EH; Lim KH; Takano A; Krisna SS; Thu MM; Liew HP; Ullrich A; Lim WT; Chua BT
Mol Cancer; 2014 Jan; 13():13. PubMed ID: 24461128
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutations in non-small cell lung cancer.
Riely GJ; Marks J; Pao W
Proc Am Thorac Soc; 2009 Apr; 6(2):201-5. PubMed ID: 19349489
[TBL] [Abstract][Full Text] [Related]
34. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer.
Iwasaki Y; Sunaga N; Tomizawa Y; Imai H; Iijima H; Yanagitani N; Horiguchi K; Yamada M; Mori M
Ann Surg Oncol; 2010 Aug; 17(8):2222-8. PubMed ID: 20155399
[TBL] [Abstract][Full Text] [Related]
36. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
38. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
39. Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation.
Grasso D; Bintz J; Lomberk G; Molejon MI; Loncle C; Garcia MN; Lopez MB; Urrutia R; Iovanna JL
Sci Rep; 2015 Nov; 5():17549. PubMed ID: 26617245
[TBL] [Abstract][Full Text] [Related]
40. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
